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A protocol for a feasibility randomised
controlled trial to assess the difference
between functional bracing and plaster
cast for the treatment of ankle fractures
Rebecca S. Kearney1*, Nick Parsons2, Dipesh Mistry1, Jonathan Young3, Jaclyn Brown1,
Joanne O’Beirne-Elliman1 and Matthew Costa4
Abstract
Background: UK Hospital Episode Statistics 2013–2014 recorded 57,286 fractures of the lower limb including the
ankle. This figure is expected to continue to increase due to a greater population of older adults. Following an ankle
fracture, patients usually have their ankle immobilised with a plaster cast. This provides maximum support for the
healing ankle but is associated with stiffness and muscle wasting. A Cochrane Review has concluded that functional
bracing may reduce muscle wasting and speed recovery of ankle movement.
The aim of this study is to determine the feasibility of conducting a full randomised controlled trial in adults with an
ankle fracture followed by functional bracing and exercises versus standard plaster cast care.
Methods: This is a single-centre feasibility randomised controlled trial. All patients with a fractured ankle are potentially
eligible. The trial will employ 1:1 random allocation, stratified by age and non-operative/operative management. Baseline
demographic and pre-injury functional data, the Manchester-Oxford Foot and Ankle Questionnaire (MOXFQ) and Olerud
and Molander Ankle Score (OMAS) will be collected alongside the EuroQol EQ-5D-5 L health-related quality of life
questionnaire. A research associate will perform a clinical assessment and obtain X-rays in 6 weeks and 6 months post
randomisation to record complications. Functional outcome and health-related quality of life will be collected in
6 weeks, 3 and 6 months post randomisation.
Discussion: This feasibility trial will provide authoritative high-quality evidence to inform the design of a definitive trial in
this important area.
Trial registration, sponsorship and funding: This study is registered with the ISRCTN (ISRCTN17809322), assigned 5
November 2015 and approved by the NRES Committee (The Black Country, 15/WM/0340), protocol version 2.0 (17
November 2015). It is co-sponsored by the University Hospitals Coventry and Warwickshire NHS Trust and University of
Warwick and funded by the NIHR Research for Patient Benefit (PB-PG-0614-34009). The trial sponsors have no direct
involvement in any aspects of study design, conduct or decision to submit the report for publication.
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Background
UK Hospital Episode Statistics 2013–2014 recorded
57,286 fractures of the lower limb including the ankle,
affecting between 107 and 187 per 100,000 persons
[1, 2]. The short-term impact of this injury results
in physical impairments, including pain, stiffness,
weakness and swelling. The longer-term impact
often includes prolonged time off work, develop-
ment of post-traumatic arthritis and psychological
consequences of depression and anxiety [3].
The main bones of the ankle are the talus (in the foot)
and the tibia and fibula (in the leg). Distally, the tibia
and fibula are bound by a fibrous band called the syn-
desmosis and have ligament attachments on the inside
of the ankle (deltoid ligament) and outside of the ankle
(lateral collateral ligaments) which are important for
ankle stability. Ankle fractures that occur below the level
of the syndesmosis are usually managed with functional
braces. Ankle fractures that occur at the level of the syn-
desmosis can lead to instability, with some requiring
open reduction and internal fixation (ORIF) with the
aim of restoring stability [3].
For ankle fractures that occur at the level of the syn-
desmosis, regardless of the decision to operate or not,
the immediate rehabilitation has traditionally been plas-
ter cast immobilisation and non-weight-bearing for sev-
eral weeks. A cast provides maximum support; however,
there are potential problems including the immediate
impact on mobility for a period of around 6 weeks and
risks associated with prolonged immobilisation such as
muscle atrophy, deep vein thrombosis and joint stiffness.
There are also long-term consequences, which can in-
clude prolonged gait abnormalities, persistent calf
muscle weakness and an inability to return to previous
activity levels. Alternative functional bracing may poten-
tially address these issues [4]. However, it does not pro-
vide the same degree of support to the healing bones [3].
This topic was addressed by a Cochrane Review in
2012 [5]. It concluded that functional bracing may im-
prove functional outcome, pain and improve ankle
movement. However, these potential advantages needed
to be balanced against the increased incidence of adverse
events. Consequently, future research was recommended
to confirm the clinical and cost-effectiveness of func-
tional bracing following an ankle fracture [5]. In light of
the large personal and societal cost associated with the
injury, this gap in the evidence is a clear priority.
In 2010, an orthopaedic trauma network (AOUK)
undertook a research priority exercise [6]. One of the
top priority questions was to establish if there is a clin-
ical advantage to wound healing and ankle function of
different rehabilitation plans following an ankle fracture.
The aim of this feasibility trial is to derive suffi-
ciently precise estimates of unknown study population
parameters (e.g. outcome variability) such that the
feasibility of conducting a full randomised controlled
trial (RCT) can be determined. The full RCT will as-
sess the difference in the Manchester-Oxford Foot
and Ankle Questionnaire (MOXFQ) in 6 months after
injury between adults with an ankle fracture followed
by functional bracing and exercises versus standard
plaster cast care.
Methods
Research question
Is it feasible to conduct a full RCT to assess the differ-
ence in the MOXFQ in 6 months after injury between
adults with an ankle fracture followed by functional
bracing and exercises versus standard plaster cast care?
Objectives
1. Evaluate the distributional properties of the
MOXFQ in order to estimate the likely sample size
required for a full RCT
2. Evaluate the number of eligible patients within the
recruiting site
3. Evaluate the willingness of clinicians to recruit
participants (the proportion of eligible patients who
are offered participation in the study)
4. Evaluate the willingness of participants to be
randomised (the proportion of eligible patients who
agree to participate in the study)
5. Evaluate the follow up and response rates to
questionnaires
6. Refine the statistical analysis plan to provide the
most efficient and sensitive analysis
7. To discuss the feasibility trial at a national consensus
meeting to inform the design of a full RCT
Design
This is a single-centre feasibility randomised controlled
trial. All patients with a fractured ankle under the care
of an orthopaedic consultant in a single UK major
trauma centre are potentially eligible. The trial will
employ 1:1 random allocation, stratified by age and
operative/non-operative management, implemented using
a remote, independent telephone randomisation service.
A total of 50 participants will be randomised.
All participants will follow a standardised protocol for
both treatments. Baseline demographic data and pre-
injury functional data using the MOXFQ and Olerud
and Molander Ankle Score (OMAS) will be collected
alongside the EuroQol EQ-5D-5 L health-related quality
of life questionnaire.
A research associate will perform a clinical assessment
and obtain X-rays in 6 weeks and 6 months to record
any early and late complications. Functional outcome
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and health-related quality of life will be collected in 6
weeks, 3 and 6 months post randomisation.
Participants
In standard clinical practise, a patient will first present
to the health professional with a history of ‘twisting’ on
the ankle or ‘falling’ [2]. The patient will then have an
initial X-ray, followed by a discussion with the health
professional about their injury that requires surgery and
the type of immobilisation required.
In this clinical trial, all adult patients with an ankle
fracture for which the treating clinician would tradition-
ally treat the patient in a plaster cast will be considered.
In this pragmatic design, this is the primary and most
important inclusion criteria. Patients who lack capacity
under the Mental Capacity Act 2005, have open ankle
fractures, who require close contact casting, have patho-
logical fractures (e.g. known metastatic disease) or any
other concurrent lower limb injury that would affect the
functional outcome measures (including bilateral ankle
fractures and syndesmosis injury requiring surgery) will
be excluded.
Screening logs will be collected to assess the main
reasons for patient exclusions, as well as the number of
patients unwilling to take part. These broad eligibility
criteria will ensure that the results of the study can read-
ily be generalised to the wider patient population.
Intervention and comparator
All patients
All patients having ankle fixation surgery will have the
preferred technique of the operating surgeon. A copy of
the ‘operating record’ will form part of the trial dataset,
including the grade and experience of the surgeon. All
patients will then be placed in a back slab until the
stitches are removed 10 days post-operatively, at which
point the intervention will be applied.
All patients not receiving surgery will be approached
to take part in the trial on first presentation to the
trauma team fracture clinic.
Control group: standard plaster cast
All patients in the control arm will be immobilised with
a plaster cast, as per standard practise; the cast may be
Plaster of Paris or fibreglass. To monitor compliance, all
patients will be asked to complete a daily dairy of how
much they bear weight.
Intervention group: functional bracing
All patients in the intervention arm will be fitted with a
removable functional brace. A functional brace is a plas-
tic shell in the shape of a boot, covering the whole foot
and leg below the knee, and it has an inner foam liner
that is held in place with Velcro. The exact choice of
removable functional brace (manufacturer, model, etc.)
will reflect the usual hospital stock available, reflecting
the pragmatic nature of this study.
Whilst wearing the functional brace, patients will be
encouraged to remove their functional brace to complete
active unloaded ankle range of movement exercises three
times per day, completing ten repetitions on each occa-
sion. To monitor compliance and intervention fidelity,
all patients will be asked to complete a daily exercise
diary.
Six weeks post treatment, all patients (operative and
non-operative) will receive the same standardised, writ-
ten physiotherapy advice detailing the exercises they
need to perform. In this pragmatic trial, any other
rehabilitation input beyond the written physiotherapy
advice (including a formal referral to physiotherapy) will
be left to the discretion of the treating clinicians. How-
ever, a record of any additional rehabilitation input (type
of input and number of additional appointments) together
with a record of any other investigations/interventions
will be requested as part of the 3- and 6-month follow-
up data.
Post randomisation withdrawals
Participants may be discontinued from the trial treat-
ment and/or the trial at any time without prejudice. Un-
less a participant explicitly withdraws their consent, they
will be followed up wherever possible and data will be
collected as per the protocol until the end of the trial.
Concomitant illness
Details of any concomitant illness will be recorded at
trial entry and all except those outlined in the exclusion
criteria are permitted during the trial.
Outcomes
Patient-centred outcomes
Baseline data will be collected by the research associates
from all participants and will include age, sex, general
medical history and pre-injury functional and health sta-
tus. This will be followed by ascertaining the current
function and health status of the patient.
Link to objectives 1 and 6: evaluate the distributional
properties of the MOXFQ in order to estimate the likely
sample size required for a full RCT. Refine the statistical
analysis plan to provide the most efficient and sensitive
analysis.
The primary functional status outcome measure for
this study is the MOXFQ. Other commonly used foot
and ankle scores include the Olerud Molander Ankle
Score (OMAS) and American Orthopaedic Foot and
Ankle Score (AOFAS); however, they lack a methodo-
logically robust approach in their development, in
contrast to the MOXFQ. The MOXFQ is a validated
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questionnaire which is self-reported (filled in by the pa-
tient). It contains 16 items, each with five response op-
tions comprising three separate underlying dimensions:
walking/standing problems (seven items), foot pain (five
items) and issues related to social interaction (four
items). Item responses are each scored from 0 to 4, with
4 representing the most severe state. The scale scores
representing each dimension are produced by summing
the responses to each item within that dimension. Raw
scale scores are then converted to a metric (0–100;
100 = most severe) [7]. This will be collected to allow
the distributional properties to be evaluated for a later
sample size calculation.
Link to objective 2: evaluate the follow up and re-
sponse rates to questionnaires
The secondary objective measures proposed for the
full RCT are health-related quality of life outcome meas-
ure for this study is the EQ-5D-5 L. The EQ-5D-5 L is a
validated, generic health-related quality of life measure
consisting of five dimensions each with a five-level an-
swer possibility. Each combination of answers can be
converted into a health utility score. It has good test-
retest reliability, is simple for patients to use and gives a
single preference-based index value for health status that
can be used for broader cost-effectiveness comparative
purposes [8]. Although cost-effectiveness analysis is not
being carried out as part of this study, it is planned to be
included in the definitive study. The methods will adhere
to the recommendations of the NICE reference case,
which included collection of EQ-5D-5 L. A record of all
complications will also be included. The team will evalu-
ate the proportion of these questionnaires that are com-
pleted and returned.
Radiographic evaluation of routine pre- and post-
injury X-rays (taken at baseline, 6 weeks and 6 months
after the injury) will also be collected from the trial
team. Standard measurements of joint congruence, frac-
ture angulation, fibular shortening and subluxation will
be assessed [9]. We will again evaluate the proportion of
these returned.
Whilst the exact number of appointments varies, most
patients will be kept under review for 6 months as part
of normal practise. The trial procedures will therefore
mirror usual care with collection of all outcome mea-
sures at baseline, 6 weeks and 6 months face to face by a
research associate in the follow-up fracture clinic. This
will be alongside postal follow up in 3 months post in-
jury. We will use techniques common in long-term
cohort studies to ensure minimum loss to follow-up,
such as collection of multiple contact addresses and tele-
phone numbers, mobile telephone numbers and email
addresses [10]. Refer to Table 1 for participant timeline.
Feasibility outcomes
Link to objectives 3, 4 and 5: evaluate the number of
eligible patients within the recruiting site; evaluate the
willingness of clinicians to recruit participants (the pro-
portion of eligible patients who are offered participation
in the study); evaluate the willingness of participants to
be randomised (the proportion of eligible patients who
agree to participate in the study).
As part of the trial processes, designated research as-
sociates will attend daily trauma meetings and fracture
clinics held at the trial site. At these locations, they will
identify potentially eligible patients who will be entered
on a screening log. These logs will contain details of
Table 1 Schedule of enrolment, interventions and assessments
Enrolment Allocation Post-allocation
Timepoint 6 weeks (±2 weeks) 3 months (±1 month) 6 months (±1 month)
Enrolment
Eligibility screen X
Informed consent X
Allocation X
Interventions
Functional brace X X
Plaster cast X X
Assessments
Demographic data X
EQ5D-5 L/MOXFQ/OMAS X X X X
Complications X X X
Exercise diary X
Physiotherapy input X X X
Radiographs X X X
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every patient who attends the trial site with an ankle
fracture. The TMG will then monitor the number of
screened patients who were eligible and offered partici-
pation for the trial and the number offered the trial who
agree to participate.
Link to objective 7: to discuss the feasibility trial at a
national consensus meeting to inform the design of a full
RCT.
All the above outcomes will be discussed at a national
consensus meeting to discuss more fully with patient,
clinician and research representatives the feasibility of
conducting a full RCT.
Sample size
As this is a feasibility study, a formal power analysis for
the sample size will not be undertaken, as the study is
not designed to test a specific null hypothesis and infer
significance to any observed treatment differences. In-
stead, we adopt a more informal approach, based on the
aims of (i) assessing the distributional properties of the
MOXFQ (specifically the variance) and (ii) assessing the
likely participation rate (the proportion of eligible pa-
tients who are likely to agree to participate in the study).
For the first aim, 50 participants in total, 25 in each arm,
will be analysed. A sample size of 50 will allow us to es-
timate a participation rate of 75% to within a 95% confi-
dence interval of ±12%. The data obtained from this
study will inform the power analysis for the full study
[11, 12].
Recruitment
Potentially eligible participants will be identified by the
patients clinical care team in the emergency department,
fracture clinics and trauma wards. The trauma team will
undertake the initial approach, explaining that a study of
ankle fracture rehabilitation is being conducted. If the
patient is willing to be approached, a suitably qualified
person will then provide verbal and written information
about the study.
This feasibility study will specifically inform the re-
cruitment rate for the main trial. However, recruitment
has been estimated on audit data at the lead centre [13]
and previous research in a related area completed at
Warwick Clinical Trials Unit [14]. In the lead centre
audit, 176 ankle fractures presented for an ankle path-
way over a 16-month period, approximately 11 per
month.
Assignment of interventions
Pre-randomisation eligibility checks will be carried out
to ensure that patients meet the eligibility criteria. Writ-
ten informed consent for entry into the trial will be ob-
tained prior to randomisation.
Allocation will be made using a secure, centralised
computer-generated allocation sequence, using a
telephone-based, independent randomisation service.
A suitably qualified member of the research team
will inform the treating clinical team of the allocated
treatment.
Stratification on the basis of age will be used to dis-
criminate between younger patients with normal bone
quality sustaining high-energy fractures (under 50 years),
and older patients (over 50 years) with low-energy
(fragility) fractures related to osteoporosis [15, 16]. A
second stratification, based on whether the patient re-
ceives surgery or not, will also be used. This will ensure
that any effect related to severity of injury is equally dis-
tributed amongst the trial arms.
Blinding
As the type of rehabilitation used is clearly visible, the
participants cannot be blinded to their treatment. In
addition, the treating surgeons cannot be blinded to the
treatment but will take no part in the assessment of
patients.
The questionnaire data will be collected and entered
onto the trial central database via postal mechanisms by
a research assistant/data clerk in the trial central office.
All X-ray data will be reviewed by two independent as-
sessors. The independent assessors will have no part in
study procedures and will therefore be blinded to treat-
ment allocation.
Data
Collection, management and monitoring
All electronic identifiable information will be held on a
secure, password-protected database accessible only to
essential personnel. Paper forms with identifiable infor-
mation will be held in secure, locked filing cabinets
within a restricted area. Personal data collected during
the trial will be handled and stored in accordance with
the 1998 Data Protection Act. Participants will be identi-
fied by a code number only. Direct access to source
data/documents will be required for trial-related moni-
toring by authorised personnel only. All paper and elec-
tronic data will be retained for at least 10 years after
completion of the trial.
The trial coordinator and data clerk will check and
enter the data onto the trial database, which will be
developed by the Programming Team at Warwick
Clinical Trials Unit. Promotion of data quality will be
achieved through implementation of a data management
plan held at the Warwick Clinical Trials Unit.
Analysis
Members of the trial management group, University of
Warwick, University of Oxford and University Hospitals
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Coventry and Warwickshire NHS Trust, will have access
to the final trial dataset. Given the small sample size, it
is unlikely that formal hypothesis testing will be useful
or informative. This data will be analysed using the soft-
ware package STATA and will be presented using stand-
ard methods for statistical summaries of discrete and
continuous data sets.
All data will be analysed and reported in accordance
with the CONSORT statement. Baseline data will be
summarised to check comparability between treatment
arms and to highlight any characteristic differences be-
tween those individuals in the study, those ineligible and
those eligible but withholding consent. As this is a feasi-
bility study, the analysis will be performed through de-
scriptive statistics rather than formal hypothesis testing.
Results will be pooled and summarised using standard
methods as appropriate and presented graphically to aid
interpretation. Standard statistical summaries and graph-
ical plots showing correlations will be presented for the
primary outcome measure (MOXFQ) and all secondary
outcome measures.
An exploratory linear regression analysis will also be
undertaken in order to explore treatment group effects,
after adjusting for the effects of patient age, fixation/
non-operative management and gender.
Temporal patterns of any complications will be pre-
sented graphically, and if appropriate, a time-to-event
analysis (Kaplan-Meier survival analysis) will be used to
assess the overall risk and risk within individual classes
of important complications (e.g. infection). The decision
about whether to undertake a time-to-event analysis will
be data-dependent, that is it will be dependent on the
number of complications reported by study participants.
It seems likely that some data may not be available
due to voluntary withdrawal of participants, lack of
completion of individual data items or general loss to
follow-up. Where possible, the reasons for data ‘miss-
ingness’ will be ascertained and reported. Although
missing data is not expected to be a problem for this
study, the nature and pattern of the missingness will be
carefully considered—including in particular whether
data can be treated as missing completely at random or
missing at random. Reasons for ineligibility, non-
compliance, withdrawal or other protocol violations will
be stated and any patterns summarised. More formal
analysis, for example using logistic regression with
‘protocol violation’ as a response is unlikely to be useful
given the small sample size but may be considered if
appropriate to aid interpretation.
Statistical methods for calculating the definitive RCT
sample size will follow the conventional approach using
four parameters: type I error, power, assumptions in the
control group (response rate and standard deviation)
and expected treatment effect.
Monitoring
As this is a single-site feasibility study, a data monitoring
committee and trial steering committee have not been
convened. There is no planned interim analysis.
The trial will be monitored by the trial management
group, who are employed by the sponsor and supported
by the funder. The trial management group will meet
monthly to discuss progress against key milestones and
be responsible for reporting to the sponsor and funder.
Reporting of SAE
An adverse event (AE) is defined as any untoward med-
ical occurrence in a participant which does not necessar-
ily have a causal relationship with this treatment/
intervention. All AEs will be listed on the appropriate
case report form (CRF) for routine return to the ‘AIR’
central office.
A serious adverse event is an AE that fulfils one or
more of the following criteria:
 Results in death
 Is immediately life-threatening
 Requires hospitalisation or prolongation of existing
hospitalisation
 Results in persistent or significant disability or
incapacity
 Is a congenital abnormality or birth defect
 Is an important medical condition
All serious adverse events (SAE) will be entered onto
the serious adverse event reporting form and faxed to
the ‘AIR’ central office within 24 h of the investigator be-
coming aware of them. Once received, causality and
expectedness will be confirmed by the chief investigator.
SAEs that are deemed to be unexpected and possibly re-
lated to the trial interventions will be notified to the
Research Ethics Committee (REC) within 15 days. All
such events will be reported to the trial management
group at their next meeting.
SAEs that may be expected as part of the interventions
and that do not need to be reported to the coordinating
centre are complications of anaesthesia or surgery (e.g.
wound complications, infections, damage to a nerve or
blood vessel and thromboembolic events) and secondary
operations for or to prevent infection, malunion, non-
union or for symptoms related to the metalwork. These
will be recorded on the participant’s CRF. All partici-
pants experiencing SAEs will be followed-up as per
protocol until the end of the trial.
Auditing
We will institute a rigorous programme of quality con-
trol. The chief investigator in conjunction with the trial
coordinator will be responsible for ensuring adherence
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to the trial protocols at the trial sites. Quality assurance
checks will be undertaken by University of Warwick to
ensure integrity of randomisation, study entry proce-
dures and data collection. The University has a quality
assurance manager who will monitor this trial by con-
ducting regular (yearly or more if deemed necessary) in-
spections of the Trial Master File.
Ethics and dissemination
This study was approved by the NRES Committee – The
Black Country, REC ref: 15/WM/0340 Version 1.0 ap-
proved 21 October 2015, and Protocol 2.0 was approved
17 November 2015. All changes are documented in the
trial site file and communicated with the REC, lead site,
sponsor and funder.
The dissemination strategy will consist of three
strands. The first will ensure that patients and public are
informed of the trial results via publication and online
resources; the second will engage practitioners and
health care planners nationally via publication and con-
ference presentations and the third will involve consult-
ing with networks for future planning of a full
application.
Discussion
This feasibility study will answer the question regarding
whether a definitive UK multi-centre RCT in this im-
portant area can be achieved. It will also provide au-
thoritative high-quality evidence to inform the definitive
trial design.
Randomised trials in a trauma setting are often laden
with barriers and uncertainties. Specifically, for this trial,
it is imperative that processes are refined to identify pa-
tients as they present into a busy clinical environment
and once identified are provided with the trial informa-
tion. Willingness of clinicians to include identified par-
ticipants will be a key driver determining the future
feasibility of this study alongside the willingness of pa-
tients to participate. These aspects will be carefully mon-
itored by the trial management group on a monthly
basis, and key documents will be refined in response to
feedback from the lead site.
Understanding and reducing potential barriers to enrol-
ment from both a clinician and patient perspectives is an
important factor alongside the quantitative measures of
the proportion of eligible patients who consent/clinicians
put forward for enrolment. However, this more in-depth
qualitative aspect is not included in this trial due to re-
source constraints. Including a qualitative component
would have also enabled further exploration of the trial
flow and processes from the experiences of those who
took part, but for reasons outlined, this was not a facet we
could include and a limitation of this protocol.
This study will be invaluable to confirm whether our
planned approach is suitable and will generate data that
will facilitate the final size and design of a definitive UK
multi-centre RCT.
Additional file
Additional file 1: Example of Consent Form. (DOC 123 kb)
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